FDA approves Novartis Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer
NVS•FDA approval expands Pluvicto use in prostate cancer
- Novartis won FDA clearance for Pluvicto with an ARPI in PSMA-positive metastatic hormone-sensitive prostate cancer.
- Phase III PSMAddition showed a 33% lower risk of progression or death at updated analysis; overall survival trended better (HR 0.80).
- Label expansion extends use across PSMA-positive metastatic prostate cancer, nearly doubling the eligible patient pool.
